Spots Global Cancer Trial Database for ociperlimab
Every month we try and update this database with for ociperlimab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer | NCT05809895 | Triple Negative... | Ociperlimab Tislelizumab Paclitaxel Nab-paclitaxel Carboplatin Placebo Pembrolizumab Gemcitabine | 18 Years - | Novartis | |
| Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer | NCT05809895 | Triple Negative... | Ociperlimab Tislelizumab Paclitaxel Nab-paclitaxel Carboplatin Placebo Pembrolizumab Gemcitabine | 18 Years - | Novartis | |
| Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors | NCT04047862 | Locally Advance... | Ociperlimab Tislelizumab Pemetrexed Paclitaxel Nab paclitaxel Carboplatin Cisplatin Etoposide 5fluorouracil Oxaliplatin Capecitabine | 18 Years - | BeiGene | |
| AdvanTIG-203: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma | NCT04732494 | Esophageal Squa... | Tislelizumab Ociperlimab Placebo | 18 Years - | BeiGene | |
| Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies | NCT04164199 | Advanced Malign... | Tislelizumab Pamiparib Temozolomide Sitravatinib Ociperlimab BAT1706 Fruquintinib BGB-15025 Zanidatamab BGB-A445 Surzebiclimab Lenvatinib LBL-007 | 18 Years - | BeiGene | |
| A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC | NCT04948697 | Advanced Hepato... | Ociperlimab Tislelizumab BAT1706 | 18 Years - | BeiGene | |
| AdvanTIG-203: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma | NCT04732494 | Esophageal Squa... | Tislelizumab Ociperlimab Placebo | 18 Years - | BeiGene | |
| A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC | NCT04948697 | Advanced Hepato... | Ociperlimab Tislelizumab BAT1706 | 18 Years - | BeiGene | |
| Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies | NCT04164199 | Advanced Malign... | Tislelizumab Pamiparib Temozolomide Sitravatinib Ociperlimab BAT1706 Fruquintinib BGB-15025 Zanidatamab BGB-A445 Surzebiclimab Lenvatinib LBL-007 | 18 Years - | BeiGene | |
| Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC. | NCT05791097 | Non-small Cell ... | Ociperlimab Placebo Tislelizumab Pembrolizumab Carboplatin Cisplatin Pemetrexed Paclitaxel Nab-paclitaxel | 18 Years - | Novartis | |
| Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors | NCT04047862 | Locally Advance... | Ociperlimab Tislelizumab Pemetrexed Paclitaxel Nab paclitaxel Carboplatin Cisplatin Etoposide 5fluorouracil Oxaliplatin Capecitabine | 18 Years - | BeiGene | |
| A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Patients With Stage III Unresectable Non-Small Cell Lung Cancer | NCT04866017 | Non Small Cell ... | Tislelizumab Durvalumab Ociperlimab | 18 Years - | BeiGene | |
| Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer | NCT04952597 | Limited Stage S... | Ociperlimab Tislelizumab Concurrent Chem... | 18 Years - | BeiGene | |
| Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC. | NCT05791097 | Non-small Cell ... | Ociperlimab Placebo Tislelizumab Pembrolizumab Carboplatin Cisplatin Pemetrexed Paclitaxel Nab-paclitaxel | 18 Years - | Novartis | |
| Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer | NCT05014815 | Locally Advance... Nonsmall Cell L... | Ociperlimab Tislelizumab histology-based... Placebo | 18 Years - | BeiGene | |
| A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer | NCT04746924 | Non-small Cell ... NSCLC | Tislelizumab Ociperlimab Pembrolizumab Placebo | 18 Years - | BeiGene |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
